Current Concepts in Histocompatibility During Heart Transplant

Experimental and Clinical Transplantation

Volumn 10, Issue 3, 2012, Pages

  Picascia, Antonietta ^a   Grimaldi, Vincenzo ^a   Zullo, Alberto ^b,c   Infante, Teresa ^d   Maiello, Ciro ^e   Crudele, Valeria ^a   Sessa, Marcella ^a   Mancini, Francesco P ^a,b   Napoli, Claudio ^a,d  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF SANNIO   (Italy)

^c CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^d IRCCS SDN   (Italy)

^e MONALDI HOSPITAL   (Italy)

Author keywords

Anti HLA antibodies; Heart; Human leukocyte antigen; Sensitized patients; Transplant

Indexed keywords

BORTEZOMIB; DACLIZUMAB; HLA ANTIBODY; HLA ANTIGEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; TACROLIMUS;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; DESENSITIZATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEART GRAFT; HLA MATCHING; HUMAN; IDIOPATHIC DISEASE; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; OUTCOME ASSESSMENT; PLASMAPHERESIS; REVIEW; SENSITIZATION; SURVIVAL RATE; SURVIVAL TIME;

EID: 84864837927     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: 10.6002/ect.2011.0185     Document Type: Review

References (80)

1. Aurora P, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric lung and heart-lung transplantation report--2010. J Heart Lung Transplant. 2010;29(10):1129-1141.
2. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant. 2011;11(6):1226-1235.
3. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation. 2008;86(3):377-383.
4. Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon. 2011;9(3):160-167.
5. Colvin RB. Dimensions of antibody-mediated rejection. Am J Transplant. 2010;10(7):1509-1510.
6. Crudele V, Picascia A, Infante T, Grimaldi V, Maiello C, Napoli C. Repeated immune and non immune insults to the graft after heart transplantation. Immunol Lett. 2011;141(1):18-27.
7. Sánchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology. 2011;140(1):51-64.
8. Weiss MJ, Madsen JC, Rosengard BR, Allan JS. Mechanisms of chronic rejection in cardiothoracic transplantation. Front Biosci. 2008;13:2980-2988.
9. Velez M, Johnson MR. Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando). 2009;23(4):235-247.
10. Shahzad K, Aziz QA, Leva JP, et al. New-onset graft dysfunction after heart transplantation--incidence and mechanism-related outcomes. J Heart Lung Transplant. 2011;30(2):194-203.
11. Kobashigawa JA, Patel JK, Kittleson MM, et al. The long-term outcome of treated sensitized patients who undergo heart transplantation. Clin Transplant. 2011;25(1):E61-E67.
12. Bray RA, Gebel HM. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant. 2009;14(4):392-397.
13. Tait BD, Hudson F, Brewin G, Cantwell L, Holdsworth R. Solid phase HLA antibody detection technology--challenges in interpretation. Tissue Antigens. 2010;76(2):87-95.
14. Eckman PM. Immunosuppression in the sensitized heart transplant recipient. Curr Opin Organ Transplant. 2010;15(5):650-656.
15. Zachary A, Reinsmoen NL. Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant. 2011;16(4):410-415.
16. Held PJ, Kahan BD, Hunsicker LG, et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med. 1994;331(12):765-770.
17. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. 2011;11(10):2132-2143.
18. Sage D. My approach to the immunogenetics of haematopoietic stem cell transplant matching. J Clin Pathol. 2010;63(3):194-198.
19. Hosenpud JD, Edwards EB, Lin HM, Daily OP. Influence of HLA matching on thoracic transplant outcomes. An analysis from the UNOS/ISHLT Thoracic Registry. Circulation. 1996;94(2):170-174.
20. Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. N Engl J Med. 1994;330(12):816-819.
21. Smith JD, Rose ML, Pomerance A, Burke M, Yacoub MH. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet. 1995;346(8986):1318-1322.
22. Sheldon S, Hasleton PS, Yonan NA, et al. Rejection in heart transplantation strongly correlates with HLA-DR antigen mismatch. Transplantation. 1994;58(6):719-722.
23. Ketheesan N, Tay GK, Witt CS, Christiansen FT, Taylor RR, Dawkins RL. The significance of HLA matching in cardiac transplantation. J Heart Lung Transplant. 1999;18(3):226-230.
24. Kaczmarek I, Deutsch MA, Rohrer ME, et al. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies? J Heart Lung Transplant. 2006;25(9):1057-1062.
25. Almenar L, Maeso ML, Martínez-Dolz L, et al. Influence of HLA matching on survival in heart transplantation. Transplant Proc. 2005;37(9):4001-4005.
26. Tenderich G, Zittermann A, Prohaska W, Koerfer R. No evidence for an improvement of long-term survival by HLA matching in heart transplant recipients. Transplant Proc. 2007;39(5):1575-1579.
27. Reinsmoen NL, Nelson K, Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol. 2004;13(1):63-71.
28. Mahle WT, Tresler MA, Edens RE, et al. Allosensitization and outcomes in pediatric heart transplantation. J Heart Lung Transplant. 2011;30(11):1221-1227.
29. Reinsmoen NL, Cornett KM, Kloehn R, et al. Pretransplant donorspecific and non-specific immune parameters associated with early acute rejection. Transplantation. 2008;85(3):462-470.
30. Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant. 2008;6(3):229-235.
31. Ho EK, Vlad G, Colovai AI, et al. Alloantibodies in heart transplantation. Hum Immunol. 2009;70(10):825-829.
32. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg. 2007;84(5):1556-1562; discussion 1562-1563.
33. Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol. 2011;72(1):5-10.
34. Irving C, Carter V, Parry G, Hasan A, Kirk R. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival. Pediatr Transplant. 2011;15(2):193-197.
35. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA- specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11(2):312-319.
36. Stastny P, Lavingia B, Fixler DE, Yancy CW, Ring WS. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation. 2007;84(6):738-745.
37. Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant. 2009;28(3):213-225.
38. Li F, Atz ME, Reed EF. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol. 2009;21(5):557-562.
39. Jindra PT, Zhang X, Mulder A, et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation. 2006;82(suppl 1):S33-S35.
40. Barabanova Y, Ramon DS, Tambur AR. Antibodies against HLA-DQ alpha-chain and their role in organ transplantation. Hum Immunol. 2009;70(6):410-412.
41. Iwasaki K, Miwa Y, Haneda M, Uchida K, Nakao A, Kobayashi T. Significance of HLA class I antibody-induced antioxidant gene expression for endothelial cell protection against complement attack. Biochem Biophys Res Commun. 2010;391(2):1210-1215.
42. Taflin C, Charron D, Glotz D, Mooney N. Immunological function of the endothelial cell within the setting of organ transplantation. Immunol Lett. 2011;139(1-2):1-6.
43. Bian H, Reed EF. Anti-HLA class I antibodies transduce signals in endothelial cells resulting in FGF receptor translocation, downregulation of ICAM-1 and cell proliferation. Transplant Proc. 2001;33(1-2):311.
44. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol. 2009;70(8):589-594.
45. Zeevi A, Girnita A, Duquesnoy R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res. 2006;36(1-3):255-264.
46. Everly MJ. Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival. Clin Transpl. 2010:317-322.
47. Bray RA, Tarsitani C, Gebel HM, Lee JH. Clinical cytometry and progress in HLA antibody detection. Methods Cell Biol. 2011;103:285-310.
48. Tambur AR, Bray RA, Takemoto SK, et al. Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation. 2000;70(7):1055-1059.
49. Eckman PM, Hanna M, Taylor DO, Starling RC, Gonzalez-Stawinski GV. Management of the sensitized adult heart transplant candidate. Clin Transplant. 2010;24(6):726-734.
50. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol. 2009;70(8):605-609.
51. Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30(2):158-163.
52. Vaidya S. Clinical importance of anti-human leukocyte antigenspecific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation. 2008;85(7):1046-1050.
53. Pajaro OE, George JF. On solid-phase antibody assays. J Heart Lung Transplant. 2010;29(11):1207-1209.
54. Kerman R, Lappin J, Kahan B, et al. The crossmatch may still be the most clinically relevant histocompatibility test performed. Clin Transpl. 2007:227-229.
55. Zeevi A, Lunz JG 3rd, Shapiro R. et al. Emerging role of donorspecific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol. 2009;70(8):645-650.
56. Jacob EK, De Goey SR, Gandhi MJ. Positive virtual crossmatch with negative flow crossmatch results in two cases. Transpl Immunol. 2011;25(1):77-81.
57. Stehlik J, Islam N, Hurst D, et al. Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant. 2009;28(11):1129-1134.
58. Poli F, Benazzi E, Innocente A, et al. Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: A case report. Hum Immunol. 2011;72(11):1045-1048.
59. Pereira S, Perkins S, Lee JH, et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol. 2011;72(6):492-498.
60. Ross H, Tinckam K, Rao V, West LJ. In praise of ventricular assist devices-mechanical bridge to virtual crossmatch for the sensitized patient. J Heart Lung Transplant. 2010;29(7):728-730.
61. Amico P, Hönger G, Steiger J, Schaub S. Utility of the virtual crossmatch in solid organ transplantation. Curr Opin Organ Transplant. 2009;14(6):656-661.
62. Chan M, Pearson GJ. New advances in antirejection therapy. Curr Opin Cardiol. 2007;22(2):117-122.
63. Nair N, Ball T, Uber PA, Mehra MR. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant. 2011;30(6):612-617.
64. Kobashigawa JA. Strategies in immunosuppression after heart transplantation: is less better? Circ Heart Fail. 2011;4(2):111-113.
65. Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant. 2006;20(4):476-484.
66. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant. 1999;18(7):701-706.
67. Jordan SC, Toyoda M, Kahwaji J, Vo AA. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am J Transplant. 2011;11(2):196-202.
68. Shehata N, Palda VA, Meyer RM, et al. The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. Transfus Med Rev. 2010;24(suppl 1):S7-S27.
69. Lobashevsky AL, Manwaring JE, Travis MM, et al. Effect of desensitization in solid organ transplant recipients depends on some cytokines genes polymorphism. Transpl Immunol. 2009;21(3):169-178.
70. Lietz K, John R, Schuster M, et al. Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients. Transplant Proc. 2002;34(5):1828-1829.
71. Rose ML, Smith J, Dureau G, Keogh A, Kobashigowa J. Mycophenolate mofetil decreases antibody production after cardiac transplantation. J Heart Lung Transplant. 2002;21(2):282-285.
72. Bucin D, Gustafsson R, Ekmehag B, et al. Desensitization and heart transplantation of a patient with high levels of donor-reactive antihuman leukocyte antigen antibodies. Transplantation. 2010;90(11):1220-1225.
73. Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant. 2005;24(5):628-630.
74. McGee EC Jr, Cotts W, Tambur AR, et al. Successful bridge to transplant in a highly sensitized patient with a complicated pump pocket infection. J Heart Lung Transplant. 2008;27(5):568-571.
75. Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with rituximab in cardiac transplantation. J Heart Lung Transplant. 2005;24(9):1337-1342.
76. Eckman PM, Thorsgard M, Maurer D, Kim Y, Alloway RR, Woodle, ES, Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transpl. 2009:475-478.
77. Woodle ES, Walsh RC, Alloway RR, Girnita A, Brailey P. Proteasome inhibitor therapy for antibody-mediated rejection. Pediatr Transplant. 2011;15(6):548-556.
78. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754-1761.
79. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30(12):1320-1326.
80. Grimaldi V, Napoli C. The effect of HLA-DR matching on pediatric kidney transplantation. Arch Surg. 2012;147(1):97; author reply 97-98.